Mast Cell Leukemia (MCL) (DBCOND0076279)

Identifiers

Synonyms

Malignant Mast Cell Tumors / Malignant mast cell neoplasm / Mast Cell Leukemia / Malignant mast cell tumor / Mast cell sarcoma / Malignant mast cell neoplasm (morphologic abnormality) / Mast cell sarcoma (morphologic abnormality) / Malignant mast cell tumor (disorder) / Mast-Cell Sarcoma / Mast cell leukaemia / Mast cell leukemia not having achieved remission / Mast cell leukemia (morphologic abnormality) / Leukemia, Mast-Cell / Mast cell leukemia (disorder) / Mastocytic leukaemia / Mastocytic leukemia / Malignant mastocytosis (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Avapritinib	A selective tyrosine kinase inhibitor being investigated for the treatment of multidrug resistant gastrointestinal tumors.	Mast/stem cell growth factor receptor Kittarget ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 3A4enzyme Cytochrome P450 2C9enzyme Bile salt export pumptransporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter Platelet-derived growth factor receptor alphatarget
Midostaurin	An antineoplastic agent used to treat high-risk acute myeloid leukemia (AML) with specific mutations, aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL).	Protein kinase C alpha typetarget Vascular endothelial growth factor receptor 2target Mast/stem cell growth factor receptor Kittarget Platelet-derived growth factor receptor alphatarget Platelet-derived growth factor receptor betatarget Receptor-type tyrosine-protein kinase FLT3target Cytochrome P450 3A Subfamilyenzyme Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2E1enzyme Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Cytochrome P450 3A43enzyme Protein kinase C gamma typetarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04996875	(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis	Bezuclastinib	treatment	2	recruiting
NCT02380222	Patient-Reported Outcome Questionnaire for Systemic Mastocytosis	No drug interventions	Not Available	Not Available	completed
NCT01616537	Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter	No drug interventions	Not Available	Not Available	terminated
NCT00898079	Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer	No drug interventions	Not Available	Not Available	completed
NCT00233454	Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia	Midostaurin	treatment	2	completed
NCT00006251	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT00186628	Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD	Acetaminophen Antithymocyte immunoglobulin (rabbit) Cyclosporine Diphenhydramine Filgrastim Granisetron Hydrocortisone Hydrocortisone valerate Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil Rituximab	treatment	2	completed
NCT02561988	(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies	Avapritinib	treatment	1	completed
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00014235	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT05219266	Managed Access Programs for PKC412, Midostaurin	Midostaurin	Not Available	Not Available	no_longer_available
NCT04695431	Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM	No drug interventions	Not Available	Not Available	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT01869777	Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia	No drug interventions	diagnostic	Not Available	completed
NCT01807598	Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia	Brentuximab vedotin	treatment	2	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT00387426	Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Sunitinib	treatment	2	terminated
NCT03214666	GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies	GTB-3550	treatment	1 / 2	terminated
NCT01273766	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Deferasirox	supportive_care	2	completed
NCT01053494	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer	No drug interventions	supportive_care	Not Available	completed
NCT03580655	(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis	Avapritinib	treatment	2	active_not_recruiting
NCT02415608	Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis	Ibrutinib	treatment	2	terminated